Castellano | Euskara | Français | English
DAR No 7: Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis
Share it
Similar efficacy at a higher cost
- Azithromycin in topical ophthalmic form is indicated in the treatment of susceptible strains of bacterial conjunctivitis and trachoma related conjunctivitis caused by Chlamydia trachomatis.
- The majority of purulent bacterial conjunctivitis cure spontaneously, and azithromycin has shown a similar efficacy and safety profile to tobramycin. There are no trials comparing other antibiotics.
- Although its posology is much more convenient, its cost is considerably higher than the other ophthalmic alternatives available.
- In the management of trachoma it has not proven superior to the administration of a single dose of oral azithromycin.
